Lyell Immunopharma Inc (LYEL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Lyell Immunopharma Inc stock (LYEL) is currently trading at $20.14. Lyell Immunopharma Inc PS ratio (Price-to-Sales) is 12657.07. Analyst consensus price target for LYEL is $32.50. WallStSmart rates LYEL as Sell.
- LYEL PE ratio analysis and historical PE chart
- LYEL PS ratio (Price-to-Sales) history and trend
- LYEL intrinsic value — DCF, Graham Number, EPV models
- LYEL stock price prediction 2025 2026 2027 2028 2029 2030
- LYEL fair value vs current price
- LYEL insider transactions and insider buying
- Is LYEL undervalued or overvalued?
- Lyell Immunopharma Inc financial analysis — revenue, earnings, cash flow
- LYEL Piotroski F-Score and Altman Z-Score
- LYEL analyst price target and Smart Rating
Lyell Immunopharma Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Lyell Immunopharma Inc (LYEL) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Lyell Immunopharma Inc (LYEL) Key Strengths (2)
Trading at 1.79x book value, attractively priced
53.67% held by institutions, strong professional interest
Supporting Valuation Data
Lyell Immunopharma Inc (LYEL) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -45.50%, a shrinking business
Very expensive at 12657.1x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Lyell Immunopharma Inc (LYEL) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 8.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (1.79) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (12657.07) suggest expensive pricing. Growth concerns include Revenue Growth at -45.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -87.00%, Operating Margin at -1024633.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -87.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -45.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LYEL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LYEL's Price-to-Sales ratio of 12657.07x trades 475% above its historical average of 2202.58x (95th percentile), historically expensive. The current valuation is 6% below its historical high of 13446.93x set in Mar 2026, and 3420730% above its historical low of 0.37x in Sep 2023. Over the past 12 months, the PS ratio has expanded from ~188.5x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Lyell Immunopharma Inc (LYEL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Lyell Immunopharma Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 36,000 with 46% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 144997% of revenue (52M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 46% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -33M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Lyell Immunopharma Inc.
Bottom Line
Lyell Immunopharma Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(20 last 3 months)
| Insider | Type | Shares |
|---|---|---|
SHAH, SMITAL Chief Fin. and Bus. Officer | Buy | +140,000 |
| Insider | Type | Shares |
|---|---|---|
BULIS, VERONICA SANCHEZ VP, Corporate Controller | Sell | -936 |
Data sourced from SEC Form 4 filings
Last updated: 8:27:52 AM
About Lyell Immunopharma Inc(LYEL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.